"I have basic trust in you, and I also believe in your ethics as a professional manager, but if the company is full of Mr. Lei's people, then even if I have 90% of the company Equity, it is not my company."
"I believe you can understand what I mean, I prefer to prepare in advance, the relationship between seniors and juniors is not guaranteed in front of benefits. You should know the endorphin market very well How big is it?"
Zheng Li did not shy away from his purpose and his worries about Cheng Gang and the people sent by Lei Jun.
After saying this, Cheng Gang's evaluation of Zheng Li was even higher. Everything can be done if it is forewarned, and if it is not forewarned, it will be abandoned.
As an eighteen-year-old young man, it is very difficult to keep a clear head when he gets 50 million investment from the other party.
In addition, Cheng Gang is also very curious about Li Miaomiao, what is so special about Li Miaomiao that she can entrust Zheng Li with a heavy responsibility.
"I understand your concerns, and I will prove my integrity with actions. As long as I am still in Sci-Tech Biology, I will consider its interests."
"In addition, Ms. Li, how old are you? Call you Miaomiao, do you think it's okay?"
Li Miaomiao replied: "No problem, Brother Cheng."
Cheng Gang secretly thought that the other party is also a wonderful person, and he could understand his subtext immediately:
"Miaomiao, I will give you the first Let me briefly introduce the structure of our company. For the time being, there are only the financial department, human resources department, legal department and R&D department, because our first product has not yet been officially launched."
"On the eve of the approval of our first drug , we will set up a sales department to be responsible for the sales of drugs, and the structure of a start-up biopharmaceutical company is roughly the same: finance, human resources, sales, legal affairs, and R&D."
"Such as public relations, clinical trials, quality management, etc. The company grows It will be considered after the establishment."
"We will also have our own first-line standardized production base in the future."
"Like Hengrui Medicine, they have their own production bases in many places across the country, and they also have a base integrating R&D and production in Gusu."
"In our company, Director Zheng is in charge of the R&D department, and I am in charge of other departments. You have the right to make decisions."
"My personal suggestion to you is that you mainly participate in the personnel and financial work in the early stage, so that you can have a grasp of the overall situation of the company as soon as possible."
"After you get started with the financial and personnel work, you can learn more about the business. After Cheng Gang
finished speaking, Zheng Li nodded slightly. He knew that Cheng Gang's proposal had no selfish intentions of his own. Li Miaomiao
: "Thank you Brother Cheng for your opinion. I also think it is better to start with personnel and finance first
."
Before clinical trials, qualitative analysis and preclinical trials are required, and then approval from the State Food and Drug Administration is required before human clinical trials can be carried out.
The qualitative analysis of endorphins is relatively simple, because there are previous papers for qualitative analysis, Kechuangbiology only needs to write a review.
Preclinical trials are relatively more difficult, because before the patent registration is approved, endorphins cannot be mass-produced industrially and can only be prepared by laboratory methods.
After one and a half months, Kechuang Biology completed the preclinical test work and entered the period of waiting for the approval of clinical trials.
Endorphin is very special. It is not a completely new drug. It was discovered very early, but it is not a generic drug, because no pharmaceutical company has mass-produced endorphin for sale before.
If it is a generic drug, clinical trials are not required, only bioequivalence trials are required.
Domestic biomedical patent registration is faster than ordinary patent registration, and endorphin is an innovative drug, so the registration process is even faster.
After three months, the industrialized production method of orphin has been approved by the national patent, and the results of the first phase of clinical trials have also come out.
Generally, only 20 to 80 cases are needed for the first phase of clinical trials, and 100 cases were used for the first phase of clinical trials of endorphin.
Phase I clinical trial verified the efficacy of endorphin injection, proving that its analgesic effect is better than that of morphine, among which, in the controlled experiment, it was proved that endorphin is still effective for some patients who are resistant to analgesics. works.
At the same time, the worldwide patent registration of endorphin is coming to an end.
This also led to the fact that Lei Jun's first investment of 50 million yuan was not enough, and Kechuang Biotech was about to start the second round of investment.
In fact, as early as after the patent was approved, relevant investment institutions had approached Cheng Gang and asked for a door-to-door investigation.
As soon as the first-phase clinical trial report came out, many institutions with great powers had already obtained it.
Investment institutions all believe that this is a business that can make money without losing money, and if you invest, you will make money.
At the same time, these investment institutions once again raised their evaluation of Zheng Li.
There is an insurmountable gap between laboratory products and industrial production, and many laboratory products are many years away from commercial use.
Zheng Li was able to invent a laboratory method for making endorphins, and simplified the process to achieve industrialized mass production. Investment institutions also invest in science and technology innovation for people.
All of a sudden, investment institutions poured in.
"Stephanie, you also know that I'm just the general manager, and I can't talk about the second round of investment in Kechuang Biology."
Cheng Gang looked helpless, and the recent phone calls took up a lot of his energy, because many of them were acquaintances who couldn't refuse.
Investment institutions came to harass Zheng Li if they couldn't reach him. Now he is talking to Stephanie Hui, the head of the Greater China investment department of Goldman Sachs Group.
"We are really optimistic about the prospects of Kechuangbio, and hope to participate in the second round of investment of Kechuangbio.
" Complete clinical trials to obtain FDA approval."
"Goldman Sachs can help Kechuangbio grow in all aspects."
The conditions proposed by Stephanie are what Kechuangbio urgently needs now.
Cheng Gang was unmoved. He smiled wryly and said, "Stephanie, I've heard IDG's Young, Sequoia's Tuvia, Hillhouse's George and so on tell me about
what you said." I am very excited, I am willing to let you participate in the second round of venture capital, but I am not a big boss, I don't even have any shares, I am just a manager."
"When will the second round of investment start, when will you invest? , I have no right to decide which organizations to participate in."
"You can ask Mr. Lei of Dami, he has more power than me."
Stephanie laughed: "It seems that I am bothering you, I don't need you to give me anything An affirmative answer, and you don't need to do anything against the interests of your company."
"I just want to meet Mr. Zheng, and I hope to have an afternoon tea with him, and it's best to have lunch with him."